Merrimack Pharmaceuticals (NASDAQ:MACK) is scheduled to announce its earnings results before the market opens on Tuesday, February 27th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter.
Merrimack Pharmaceuticals (NASDAQ:MACK) opened at $10.82 on Tuesday. The company has a market capitalization of $144.33, a price-to-earnings ratio of 0.32 and a beta of 1.74. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.35 and a current ratio of 3.35. Merrimack Pharmaceuticals has a 52 week low of $9.68 and a 52 week high of $39.90.
A hedge fund recently raised its stake in Merrimack Pharmaceuticals stock. The Manufacturers Life Insurance Company increased its stake in shares of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) by 14.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 113,235 shares of the biopharmaceutical company’s stock after buying an additional 14,591 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.09% of Merrimack Pharmaceuticals worth $141,000 at the end of the most recent quarter. 52.32% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This piece was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2018/02/20/merrimack-pharmaceuticals-mack-set-to-announce-quarterly-earnings-on-tuesday.html.
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.